Predicting How Adults With Depressed Mood Respond to Esketamine or Brain Stimulation
Looks at treatment results in adults with depressed mood to build prediction tools.
Plain-language title generated from the registry record
Registry title: ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
Key facts
- Where
- La Jolla and Laguna Hills, United StatesSee the 2 sites
Where in United States
- Salma HealthLa Jolla, United StatesTaking people
- Salma HealthLaguna Hills, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Salma Health, Inc.
- Trial code
- NCT07528014
- Record updated
- 14 April 2026
- Original description
This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.Read full original descriptionShow less
ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1
This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.
Inclusion: Adults (≥18 years) of any gender identity presenting for care with a depressed mood; Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care; Able to provide informed consent and comply with all study requirements.
Exclusion: Any condition deemed by the investigator to preclude safe participation in study assessments.